Proactive Investors - Run By Investors For Investors

Cello Health expects 'robust' profits growth in first half

With cash in the bank, management are eyeing acquisitions in the US
Cello Health services 24 of the top 25 pharmaceutical clients globally

Healthcare-focused consultancy Cello Health PLC (LON:CLL) is confident its second quarter will continue the “very good” start made to 2019.

Growth in like-for-like net revenue and headline profit before tax in the first quarter was described as “good” in a statement issued ahead of the AIM-listed company’s annual shareholder meeting.

The consulting businesses and the US operations put in an “excellent” performance and are expected to continue this trend in the second quarter.

Last year the company changed its name to Cello Health to reflect the new ongoing strategic focus on the healthcare sector, where it services 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech and medical equipment outfits.

Without mentioning numbers, Cello’s confidence about the second quarter led management to expect headline PBT growth for the first half of the year will be “robust”. Last year, headline PBT increased 6.4% to £12.2mln on revenue up 2.3% to £104.8mln.

Cash conversion has been better than expected, continuing the trend from last year, which finished with £6.3mln in the coffers. Management plan to put some of this cash to use through acquisitions and are assessing suitable growth opportunities in the US.

Chairman Chris Jones was quoted as saying that the year to date has been as expectated and that the board is confident of achieving a successful full year result in 2019, "in line with expectations".

View full CLL profile View Profile

Cello Health PLC Timeline

April 11 2019
Big Picture
March 22 2019

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
genedrive device
July 16 2019
Here we take a closer look at Genedrive PLC (LON:GDR)
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use